Company news

Revolution Medicines, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

October 15, 2025

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

September 28, 2025

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

September 9, 2025

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

August 5, 2025

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

July 29, 2025

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

July 23, 2025

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib

July 22, 2025

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

July 8, 2025

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

June 29, 2025

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

June 29, 2025

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

June 23, 2025

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

June 22, 2025

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

May 13, 2025

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

May 6, 2025

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

April 29, 2025

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

April 26, 2025

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

March 31, 2025

Revolution Medicines to Participate in April 2025 Investor Conferences

March 30, 2025

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

February 25, 2025

Revolution Medicines to Participate in March 2025 Investor Conferences

February 23, 2025

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

February 18, 2025

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

January 28, 2025

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

December 4, 2024

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

December 2, 2024

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

December 1, 2024

Revolution Medicines Announces Commencement of Public Offering of Common Stock

December 1, 2024

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

November 26, 2024

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

November 5, 2024

Revolution Medicines to Participate in Upcoming Investor Conferences

November 4, 2024

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

October 29, 2024

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

October 24, 2024

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

October 22, 2024

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

October 20, 2024

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

October 6, 2024

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

August 6, 2024

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

July 30, 2024

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

July 10, 2024

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

July 7, 2024

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

May 7, 2024

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

April 30, 2024

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

April 8, 2024

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

April 7, 2024

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

March 27, 2024

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

February 25, 2024

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

February 19, 2024

Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

Revolution Medicines Completes Acquisition of EQRx

November 8, 2023

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

November 7, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.